華潤醫藥：2024中期報告.pdf

《華潤醫藥：2024中期報告.pdf》由会员分享，可在线阅读，更多相关《華潤醫藥：2024中期報告.pdf（107页珍藏版）》请在三个皮匠报告上搜索。

1、02 公司簡介Corporate Profile03 公司資料Corporate Information07 釋義Definitions12 管理層討論及分析Management Discussion and Analysis49 其他資料Other Information58 獨立審閱報告Independent Review Report60 中期簡明綜合損益表Interim Condensed Consolidated Statement of Profit or Loss61 中期簡明綜合全面收益表Interim Condensed Consolidated Statement of C

2、omprehensive Income62 中期簡明綜合財務狀況表Interim Condensed Consolidated Statement of Financial Position64 中期簡明綜合權益變動表Interim Condensed Consolidated Statement of Changes in Equity66 中期簡明綜合現金流量表Interim Condensed Consolidated Statement of Cash Flows70 未經審核的中期財務資料附註Notes to the Unaudited Interim Financial Infor

3、mation此中期報告以環保紙張印製This interim report is printed with eco-friendly paper目錄Contents2024 年中期報告 華潤醫藥集團有限公司02公司簡介Corporate ProfileChina Resources Pharmaceutical Group Limited(stock code:3320)is a leading integrated pharmaceutical company in China.Our business encompasses manufacturing,distribution and r

4、etail of pharmaceutical and healthcare products.Since the establishment in 2007,the Group has developed into one of the top 5 pharmaceutical manufacturers and one of the top 3 pharmaceutical distributors(by revenue)in China.In October 2016,the Company successfully completed its global offering in Ho

5、ng Kong.Our manufacturing business encompasses the research and development,manufacturing and sale of pharmaceutical and healthcare products.We manufacture 792 products,430 of which were included in the Chinas national reimbursement drug list.The products comprise chemical drugs,Chinese medicines an

6、d biological drugs as well as nutritional and healthcare products,covering a wide range of therapeutic areas including cardiovascular,alimentary tract and metabolism,large-volume intravenous infusion,pediatrics,respiratory system,dermatology,etc.Moreover,we own a range of famous brands,such as“999”,